Akos Therapeutics

Akos Therapeutics is a clinical-stage biotechnology company focused on developing innovative topical therapies for chronic pain management. The company's lead product candidate, AK-101, is a proprietary topical formulation of amitriptyline and ketamine designed to treat Post-Herpetic Neuralgia (PHN) by providing localized relief with minimal systemic absorption. Founded by the leadership team of the telehealth provider Akos, the therapeutics division aims to address the limitations of oral neuropathic pain medications, such as dizziness and sedation. In March 2020, Akos Therapeutics was acquired by Akers Biosciences, which subsequently merged with MyMD Pharmaceuticals to continue the development of its clinical assets. The company's approach leverages localized drug delivery to improve the safety and efficacy profile of established analgesic compounds.